Breaking News Instant updates and real-time market news.

AQXP

Aquinox

$13.36

-0.26 (-1.91%)

09:18
10/03/16
10/03
09:18
10/03/16
09:18

Aquinox appoints Dr. Barbara Troupin as Chief Medical Officer

Aquinox Pharmaceuticals announced the appointment of Dr. Barbara Troupin, M.D. as Chief Medical Officer and Vice President, Clinical Development. Dr. Troupin will lead overall clinical and medical affairs strategies for Aquinox's ongoing programs as well as future development and potential commercialization plans.

AQXP Aquinox
$13.36

-0.26 (-1.91%)

10/23/15
NEED
10/23/15
INITIATION
Target $25
NEED
Buy
Aquinox initiated with a Buy at Needham
Target $25.
10/23/15
10/23/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Alnylam (ALNY) initiated with a Buy at Jefferies... Aquinox (AQXP) initiated with a Buy at Needham... CIBER (CBR) initiated with a Buy at Maxim... DBV Technologies (DBVT) initiated with a Buy at BofA/Merrill... Enbridge (ENB) initiated with an Outperform at BMO Capital... Ignyta (RXDX) initiated with a Buy at Jefferies... Marcus & Millichap (MMI) initiated with a Market Perform at Wells Fargo... PTC Therapeutics (PTCT) initiated with a Hold at Jefferies... Sarepta (SRPT) initiated with a Buy at BofA/Merrill... Tobira Therapeutics (TBRA) initiated with an Outperform at Leerink... TransCanada (TRP) initiated with an Outperform at BMO Capital... WWE (WWE) initiated with an Outperform at FBN Securities... Xtent (XTNT) initiated with a Buy at Brean Capital... bluebird bio (BLUE) initiated with a Buy at Jefferies
11/03/15
LEER
11/03/15
NO CHANGE
LEER
Outperform
Aquinox selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis recommends using the pullback in shares of Aquinox Pharmaceuticals after AQX-1125 failed in Atopic Dermatitis as a buying opportunity. AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis is the primary driver for shares, Matteis tells investors in a research note. He points out that Atopic Dermatitis was not included in his model and that investor expectations for the indication were low. Matteis keeps an Outperform rating on Aquinox.
08/04/16
08/04/16
NO CHANGE

On The Fly: After Hours Movers
UP AFTER EARNINGS: Pacific Biosciences (PACB), up 17%... MasTec (MTZ), up 9.6%... Aratana Therapeutics (PETX), up 9.2%... Lion's Gate (LGF), up 6.4%... Priceline (PCLN), up 5.7%... Ubiquiti (UBNT), up 5.5%... MercadoLibre (MELI), up 4.1%... Organovo (ONVO), up 3.9%... Kraft Heinz (KHC), up 3.3%... EOG Resources (EOG), up 2.8%... Monster Beverage (MNST), up 1.2%... TASER (TASR), up 1.2%... Take-Two (TTWO), up 0.9%... Activision Blizzard (ATVI), up 1%... BioMarin (BMRN), up 0.4%. ALSO HIGHER: Egalet (EGLT), up 31.2% after the company announced that an FDA advisory committee recommended approval of its ARYMO ER drug... Rackspace (RAX), up 17.6% after the Wall Street Journal reported that the company was near a takeover deal with a private equity buyer... Osiris (OSIR), up 8.5% after it said that the manuscript from its prospective trial using Grafix was published. DOWN AFTER EARNINGS: Hortonworks (HDP), down 26.2%... PDL BioPharma (PDLI), down 17.5%... FireEye (FEYE), down 15.8%... Sierra Wireless (SWIR), down 15.6%... Aquinox (AQXP), down 14.7%... Zynga (ZNGA), down 9.4%... Universal Display (OLED), down 8.2%... Weight Watchers (WTW), down 7.6%... Zillow Group (Z, ZG), down 5.5%... Arista Networks (ANET), down 4.5%... Noodles & Company (NDLS), down 4.3%... Merrimack (MACK), down 1.7%... Bankrate (RATE), down 1.7%.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.